Reprimo (RPRM) is a potential p53-dependent tumor suppressor gene, which plays an important role in cell cycle arrest at G(2)/M checkpoint. The aim of this study was to characterize RPRM protein expression in breast cancer tissues and its relation with clinic-pathologic features and proliferation marker protein Ki67. RPRM protein expression was examined by immunohistochemistry in tissue microarray containing 275-breast cancer and 16 normal breast tissues. These cases were classified as negative or positive expression for RPRM expression level with clinic-pathologic variables. The Kaplan-Meier curve was used to estimate survival over time. Positive expression of RPRM was observed in 68.4% (188/275) of tumors and 100% of breast normal tissues...
AbstractThe molecular mechanisms responsible for opposing oncogenic and tumor-suppressor activities ...
WOS: 000382974300005PubMed ID: 27284123Objectives. The aims of this study are to evaluate expression...
Background and Objectives Breast cancer continues to frustrate oncologists worldwide. In India, it i...
Artículo de publicación ISIReprimo (RPRM), a downstream effector of p53-induced cell cycle arrest at...
Reprimo (RPRM), a downstream effector of p53-induced cell cycle arrest at G2/M, has been proposed as...
BACKGROUND: Reprimo (RPRM), a highly glycosylated protein, is a new downstream effector of p53-induc...
Reprimo (RPRM), a downstream effector of p53-induced cell cycle arrest at G2/M, has been proposed as...
<p>The PTPRM transcript level was decreased in human breast cancer compared with normal breast tissu...
BACKGROUND: Repulsive guidance molecules (RGMs) are novel co-receptors of bone morphogenetic protein...
Mcm2-7 (MCM) proteins are part of the origin licensing machinery that regulates initiation of DNA re...
Abstract Background Hyperplasia of usual type (HUT) is a common proliferative lesion associated with...
The aim of the study was to evaluate the localization and intensity of RNA-binding motif single-stra...
<p>Increasing MMP13 followed by decreasing RKIP levels are associated with a progressive cancer dise...
Mcm2–7 (MCM) proteins are part of the origin licensing machinery that regulates initiation of DNA re...
The molecular mechanisms responsible for opposing oncogenic and tumor-suppressor activities of NF-kB...
AbstractThe molecular mechanisms responsible for opposing oncogenic and tumor-suppressor activities ...
WOS: 000382974300005PubMed ID: 27284123Objectives. The aims of this study are to evaluate expression...
Background and Objectives Breast cancer continues to frustrate oncologists worldwide. In India, it i...
Artículo de publicación ISIReprimo (RPRM), a downstream effector of p53-induced cell cycle arrest at...
Reprimo (RPRM), a downstream effector of p53-induced cell cycle arrest at G2/M, has been proposed as...
BACKGROUND: Reprimo (RPRM), a highly glycosylated protein, is a new downstream effector of p53-induc...
Reprimo (RPRM), a downstream effector of p53-induced cell cycle arrest at G2/M, has been proposed as...
<p>The PTPRM transcript level was decreased in human breast cancer compared with normal breast tissu...
BACKGROUND: Repulsive guidance molecules (RGMs) are novel co-receptors of bone morphogenetic protein...
Mcm2-7 (MCM) proteins are part of the origin licensing machinery that regulates initiation of DNA re...
Abstract Background Hyperplasia of usual type (HUT) is a common proliferative lesion associated with...
The aim of the study was to evaluate the localization and intensity of RNA-binding motif single-stra...
<p>Increasing MMP13 followed by decreasing RKIP levels are associated with a progressive cancer dise...
Mcm2–7 (MCM) proteins are part of the origin licensing machinery that regulates initiation of DNA re...
The molecular mechanisms responsible for opposing oncogenic and tumor-suppressor activities of NF-kB...
AbstractThe molecular mechanisms responsible for opposing oncogenic and tumor-suppressor activities ...
WOS: 000382974300005PubMed ID: 27284123Objectives. The aims of this study are to evaluate expression...
Background and Objectives Breast cancer continues to frustrate oncologists worldwide. In India, it i...